Basit öğe kaydını göster

Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

dc.contributor.authorBuyru, Ayse Nur
dc.contributor.authorSimsek, Eda Tanrikulu
dc.contributor.authorEkizoglu, Seda
dc.contributor.authorGulturk, Emine
dc.contributor.authorFerhanoglu, Burhan
dc.contributor.authorTuzuner, Nukhet
dc.contributor.authorDemiroz, Ahu Senem
dc.contributor.authorAydin, Seniz Ongoren
dc.contributor.authorAydin, Yildiz
dc.contributor.authorSoysal, Teoman
dc.contributor.authorOzbek, Ugur
dc.contributor.authorBaslar, Zafer
dc.contributor.authorSalihoglu, Ayse
dc.contributor.authorElverdi, Tugrul
dc.contributor.authorAr, Muhlis Cem
dc.contributor.authorEskazan, Ahmet Emre
dc.contributor.authorCengiz, Mahir
dc.date.accessioned2021-03-04T17:34:40Z
dc.date.available2021-03-04T17:34:40Z
dc.date.issued2016
dc.identifier.citationSimsek E. T. , Eskazan A. E. , Cengiz M., Ar M. C. , Ekizoglu S., Salihoglu A., Gulturk E., Elverdi T., Aydin S. O. , Demiroz A. S. , et al., "Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia", JOURNAL OF CLINICAL PATHOLOGY, cilt.69, sa.9, ss.810-816, 2016
dc.identifier.issn0021-9746
dc.identifier.othervv_1032021
dc.identifier.otherav_86535f61-414e-4be4-98d8-f2424f4b3391
dc.identifier.urihttp://hdl.handle.net/20.500.12627/91282
dc.identifier.urihttps://doi.org/10.1136/jclinpath-2015-203320
dc.description.abstractAims Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy.
dc.language.isoeng
dc.subjectPatoloji
dc.subjectPATOLOJİ
dc.subjectBiyoloji ve Biyokimya
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectBiyokimya
dc.subjectCerrahi Tıp Bilimleri
dc.subjectTıp
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.titleImatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL PATHOLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume69
dc.identifier.issue9
dc.identifier.startpage810
dc.identifier.endpage816
dc.contributor.firstauthorID234920


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster